Integration of tumour sequencing in lung cancer treatment

Speakers: Antonio Marchetti and Fred Hirsch

A. Marchetti and F. Hirsch discuss advantages of next generation sequencing, technologies employed for clinical decision making in lung cancer treatment and how to integrate different sequencing strategies. Besides current status, they briefly discuss what to expect from future discoveries in lung cancer and molecular abnormalities testing.

Discussion Points

  • Technologies to detect genetic mutations
  • Challenges in molecular testing
  • Advances of next generation sequencing
  • The need for clinical validation